Close Menu

NEW YORK (GenomeWeb) – Elucidata, a startup developer of analytics software to support drug discovery, announced today that it has raised $1.7 million in seed funding.

Hyperplane Venture Capital led the seed round, with participation from unspecified angel investors. The company said it would use the money to expand at its twin headquarters in Cambridge, Massachusetts, and in New Delhi, India. Elucidata said that it has already become profitable despite only being bootstrapped up to this point.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

According to New Scientist, GEDmatch changed its terms and conditions over the weekend to opt its users out of law enforcement searches.

The Atlantic looks into time spent pursuing gene leads generated through candidate gene studies.

A twin study uncovers evidence that genes may influence whether someone gets a dog, Martha Stewart reports.

In PNAS this week: Cdx2 cells can help regenerate heart tissue in mice following a heart attack, PIWI-interacting small RNA levels in human cancer, and more.

Sponsored by

This webinar will provide an overview of polygenic risk scores, which aggregate dozens of genetic variants that have been linked to disease risk in genome-wide association studies (GWAS) into a single score.